30 Day Trial

NuVasive Reports Preliminary 4Q16 and 2016 Revenue

Share:

NuVasive announced preliminary unaudited 2016 sales of ~US $956.0MM, +17.9% from 2015, with 4Q16 revenue of ~$265.0MM

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.